Despite having reported mixed but good figures, North America, the largest segment (the company’s segment reporting is by regions), saw a strong top-line development (including the NxStage acquisition), but profitability suffered from various effects (e.g. lower revenue per treatment and higher costs per treatment). The other regions more than offset this. The Q3 figures were above our expectations as well consensus.
29 Oct 2019
North America raises some question marks
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
North America raises some question marks
Fresenius Medical Care AG (FME:WBO) | 0 0 0.7% | Mkt Cap: 26,769m
- Published:
29 Oct 2019 -
Author:
Martin Schnee -
Pages:
3
Despite having reported mixed but good figures, North America, the largest segment (the company’s segment reporting is by regions), saw a strong top-line development (including the NxStage acquisition), but profitability suffered from various effects (e.g. lower revenue per treatment and higher costs per treatment). The other regions more than offset this. The Q3 figures were above our expectations as well consensus.